Onyda XR: Advancing ADHD Treatment
Tris Pharma, a New Jersey-based pharmaceutical company, has made a groundbreaking advancement in the treatment options available for Attention-Deficit Hyperactivity Disorder (ADHD). They have recently received FDA approval for Onyda XR (clonidine hydrochloride), the first liquid non-stimulant medication designed specifically for ADHD. What sets Onyda XR apart is that it is the only non-stimulant with nighttime dosing indicated.
For years, stimulant medications have been the go-to treatment for ADHD. However, they are not always effective for all patients and can come with challenging side effects. This is where Onyda XR steps in to offer an alternative approach. Through Tris Pharma’s LiquiXR drug delivery technology, Onyda XR provides extended-release characteristics. This means that patients only need to take it once a day, improving convenience and potentially enhancing adherence.
Ketan Mehta, CEO and founder of Tris Pharma, is optimistic about the launch of Onyda XR. He stated, “Tris anticipates having pricing details available as the launch approaches.” The medication will be available for pediatric patients aged 6 and older, either as a standalone therapy or in combination with central nervous system stimulants.
Tris Pharma’s Innovations in ADHD Treatment
Tris Pharma, a company established 24 years ago, has earned a reputation for its portfolio of specialty generics, branded products, and over-the-counter medications. However, it has also faced scrutiny in the past. Recently, the state of Texas raised allegations regarding Tris Pharma’s ADHD medication Quillivant XR, which was developed in collaboration with Pfizer.
Nevertheless, Tris Pharma has continued to push forward with its innovations in ADHD treatment. The development of Onyda XR builds upon the success of their LiquiXR technology. This technology has the ability to transform immediate-release products into extended-release formulations. In the case of Onyda XR, it has allowed them to convert clonidine, a medication originally approved by the FDA for high blood pressure treatment 50 years ago, into a medication for managing ADHD.
Tris Pharma’s efforts to expand its ADHD medication offerings demonstrate their commitment to meeting the diverse needs of patients. With the launch of Onyda XR planned for the second half of this year, the company aims to provide a viable alternative for those who do not respond well to stimulant medications. The convenience of once-daily dosing and the potential for improved adherence make Onyda XR an exciting addition to the ADHD treatment landscape.